In addition, the relationship between the 19 signature genes and the ORR of immunotherapy was explored, and the results indicated that NRIP1 could be a therapeutic target for adjuvant immunotherapy, which may provide new opportunities for the treatment of AML patients with high NRIP1 activity (Figures 7(d) and 7(e), p=0.032, Supplementary Table 10). This evidence concerns the gene NRIP1 and acute myeloid leukemia.